ScholarIQanswers from OpenAlex & ORCID
Jeremy Hamm
ResearcherPublications, citations & collaboration network
Jeremy Hamm is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeremy Hamm have?
ScholarIQindexed works
Jeremy Hamm has 87 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeremy Hamm have?
ScholarIQcitation count
Jeremy Hamm has 2,105 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeremy Hamm?
ScholarIQh-index
Jeremy Hamm has an h-index of 19 in OpenAlex.
What is the i10-index of Jeremy Hamm?
ScholarIQi10-index
Jeremy Hamm has an i10-index of 36 in OpenAlex.
What is the ORCID of Jeremy Hamm?
ScholarIQorcid
The ORCID for Jeremy Hamm is on the source record.
What is the OpenAlex record for Jeremy Hamm?
ScholarIQopenalex
The OpenAlex for Jeremy Hamm is on the source record.
What are the most-cited papers on Jeremy Hamm?
ScholarIQmost cited works
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
William Morris, Scott Tyldesley, S. Rodda, Ross Halperin, Howard Pai, Michael McKenzie, Graeme Duncan, Gerard Morton, Jeremy Hamm, Nevin Murray
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
Sree Rodda, Scott Tyldesley, William Morris, Mira Keyes, Ross Halperin, Howard Pai, Michael McKenzie, Graeme Duncan, Gerard Morton, Jeremy Hamm, Nevin Murray
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
S. Rodda, William Morris, Jeremy Hamm, Graeme Duncan
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.
William Morris, Scott Tyldesley, Howard Pai, Ross Halperin, Michael McKenzie, Graeme Duncan, Gerard Morton, Nevin Murray, Jeremy Hamm
An Updated Analysis of the Survival Endpoints of ASCENDE-RT
Justin Oh, Scott Tyldesley, Howard Pai, Michael McKenzie, Ross Halperin, Graeme Duncan, Gerard Morton, Mira Keyes, Jeremy Hamm, William Morris